A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2019
At a glance
- Drugs Iberdomide (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 01 Nov 2018 This trial has been discontinued in Germany.
- 10 Oct 2018 Planned End Date changed from 8 May 2020 to 25 Jun 2021.
- 10 Oct 2018 Planned primary completion date changed from 20 Mar 2020 to 20 May 2021.